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ABSTRACT
Background
Acute respiratory distress syndrome (ARDS) is a devastating complication of numerous
underlying conditions, most notably sepsis. Although pathologic vascular leak has been
implicated in the pathogenesis of ARDS and sepsis-associated lung injury, the mechanisms
promoting leak are incompletely understood. Angiopoietin-2 (Ang-2), a known antagonist of
the endothelial Tie-2 receptor, was originally described as a naturally occurring disruptor of
normal embryonic vascular development otherwise mediated by the Tie-2 agonist
angiopoietin-1 (Ang-1). We hypothesized that Ang-2 contributes to endothelial barrier
disruption in sepsis-associated lung injury, a condition involving the mature vasculature.
Methods and Findings
We describe complementary human, murine, and in vitro investigations that implicate Ang-2
as a mediator of this process. We show that circulating Ang-2 is significantly elevated in
humans with sepsis who have impaired oxygenation. We then show that serum from these
patients disrupts endothelial architecture. This effect of sepsis serum from humans correlates
with measured Ang-2, abates with clinical improvement, and is reversed by Ang-1. Next, we
found that endothelial barrier disruption can be provoked by Ang-2 alone. This signal is
transduced through myosin light chain phosphorylation. Last, we show that excess systemic
Ang-2 provokes pulmonary leak and congestion in otherwise healthy adult mice.
Conclusions
Our results identify a critical role for Ang-2 in disrupting normal pulmonary endothelial
function.
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Sepsis is characterized by a systemic inﬂammatory response
to a microbial pathogen. In the United States, this illness
accounts for 2%–3% of all hospital admissions (;650,000 per
year to major hospitals), carries a mortality of ;30%, and has
estimated annual direct costs in excess of $16 billion [1].
Although the mortality associated with sepsis has declined in
the past 20 years [2], it remains a common and deadly
condition. Among individuals with sepsis, those who develop
shock and multi-organ dysfunction are at greatest risk of
death [3].
Capillary permeability is a tightly regulated feature of
microcirculation in all organ beds and is fundamentally
altered in sepsis, resulting in net extravasation of ﬂuid out
of the vascular space and into tissues. A dramatic
manifestation of this phenomenon is acute respiratory
distress syndrome (ARDS), a complication that occurs in
up to 40% of patients with sepsis and is marked by leakage
of ﬂuid out of pulmonary capillaries and into alveolar septa
and air spaces [4]. Excess extravascular ﬂuid in the lung
impairs gas exchange across the alveolar membrane and
decreases lung compliance. ARDS associated with sepsis has
been correlated with adverse clinical outcomes, including
;40% mortality [5–7].
Endothelial barrier integrity is thought to be a balance
between (1) contractile forces within endothelial cells (ECs)
that permit paracellular leakage by creating intercellular gaps
and (2) adhesive forces between ECs that restrict such gaps.
Myosin light chain (MLC), in its phosphorylated form (MLC-
p), mediates contraction in a wide variety of cells, including
the microvascular endothelium. An increase in contractile
force within ECs—via MLC-p—is associated with increased
permeability [8,9]; conversely, blockade of MLC-p reduces
trans-endothelial permeability [10].
Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) are
peptide ligands that bind the Tie-2 receptor tyrosine kinase
found primarily on ECs. They were ﬁrst identiﬁed as an
agonist/antagonist pair necessary for embryonic vascular
development [11,12]. Ang-1 appears to promote vessel
stability [12,13] by recruiting pericytes to nascent blood
vessels [14] and preserving cell–cell contacts [15]. Ang-1 may
also have an anti-inﬂammatory action by signaling the down-
regulation of surface-adhesion molecules such as VCAM-1
and E-selectin [16]. Ang-1, expressed in supraphysiologic
concentrations, appears to function as an anti-permeability
agent in rodent dermal capillaries [17]. Disruptions in the
Tie-2 signaling pathway can occur in developmental lung
disorders [18], and expression of Tie-2 in quiescent adult
tissues is highest in the lung [19,20]. Together these reports
suggested (a) that an imbalance in Tie-2 signaling could arise
in the inﬂammatory milieu of sepsis, and (b) that, should such
an imbalance arise, the lung might be preferentially affected.
We therefore hypothesized that excess Ang-2 signaling may
occur in sepsis, promoting pulmonary vascular leak through
up-regulation of MLC-p. We explored this question in several
settings: (1) humans with sepsis in whom circulating Ang-2
levels were measured, (2) EC monolayers in which signaling
and structural responses to sepsis serum from humans and
recombinant human Ang-2 were assessed, and (3) a rodent
model in which vascular leak was quantiﬁed.
Methods
Patients
Every weekday during a 2-mo period, all patients admitted
during the preceding 24 h to the medical intensive care unit
at Beth Israel Deaconess Medical Center were screened for
study eligibility. Participants were identiﬁed by the parame-
ters used to deﬁne sepsis [21]. Evidence of infection (e.g.,
positive cultures, typical clinical syndrome) must have been
accompanied by two of the following four criteria: (1)
temperature , 36 8Co r. 38 8C; (2) heart rate . 90 bpm;
(3) respiratory rate . 20 bpm or PaCO2 , 32 mmHg; (4)
white blood cell count . 12,000 cells/mm
3, ,4,000 cells/mm
3,
or .10% immature forms. In a prospective fashion,
discarded serum samples and clinical data were collected on
this cohort as well as from a randomly selected control group
of patients hospitalized on the general medical service with a
variety of illnesses that did not meet criteria for sepsis. All
identifying information was removed; study specimens from
patients and clinical data were encoded to protect the privacy
of patients. Serum collected from the clinical laboratory was
aliquoted in a sterile fashion and stored in cryo-vial tubes at
 80 8C. The institutional review board of Beth Israel
Deaconess Medical Center approved this study.
ELISA
Ang-2 levels were measured in serum samples from patients
by sandwich ELISA using the reagents and protocol supplied
with the human Ang-2 ELISA kit (R&D Systems, Minneapolis,
Minnesota, United States). Preliminary experiments con-
ﬁrmed the stability of Ang-2 in serum for 6–12 h at room
temperature as well as its stability through several freeze–
thaw cycles.
Chemicals
We purchased human recombinant Ang-1 and Ang-2 from
R&D Systems. The RhoA-associated protein kinase inhibitor
Y27632 and endothelial cell myosin light chain kinase (EC
MLCK) inhibitor ML-7 were purchased from EMD Bioscien-
ces (San Diego, California, United States). Other reagents
used in the experiments were obtained from Sigma (St. Louis,
Missouri, United States).
Animals
Female FVB mice (obtained from Charles River, Wilming-
ton, Massachusetts, United States) weighing 18–25 g were
used throughout the study. All protocols were approved by
the Beth Israel Deaconess Medical Center Animal Committee.
They were acclimated to the animal facilities for at least 1 wk
before the beginning of any experiment.
Cell Culture
Human microvascular endothelial cells (HMVECs) from
neonatal dermis (Cambrex Bio Science, Walkersville, Mary-
land, United States) were cultured in EBM-2 (Cambrex Bio
Science) supplemented with 5% fetal bovine serum (FBS) and
growth factors according to the manufacturer’s instructions.
Serum starvation was performed by incubation in 0.25% FBS/
EBM-2 for 24 h.
Evans Blue Permeability Assay
Mice were injected with 10 lg of Ang-2 or vehicle
intraperitoneal, and, after 16 h, were anesthetized with
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Ang-2 in Pulmonary Vascular LeakAvertin (2,2,2-Tribromoethanol). 2% Evans blue (50 ll) was
then injected into the retro-orbital sinus. (In preliminary
experiments with control mice, n ¼ 6, we conﬁrmed that the
retro-orbital sinus provided a route of intravascular injection
that allowed near-100% delivery of Evans blue in a
reproducible fashion.) 10 min after Evans blue injection,
mice were sacriﬁced and perfused with PBS with 2mM EDTA
for 10 min through a cannula placed in the right ventricle.
Blood and PBS were vented through an incision in the vena
cava, thus allowing perfusate to pass through the pulmonary
and systemic circulations. After 10 min of perfusing the right
ventricle with PBS, the outﬂow from the vena cava was
observed to be clear, conﬁrming that blood (and intravascular
Evans blue) had been ﬂushed out of the circulation. Washout
of intravascular contents was also conﬁrmed histologically
after 10 min of PBS perfusion. Organs were then harvested
and homogenized in 1.5 ml of formamide. Evans blue was
extracted by incubating the samples at 70 8C for 24 h, and the
concentration of Evans blue was estimated by dual-wave-
length spectrophotometer (620 nm and 740 nm). The
following formula was used to correct optical densities (E)
for contamination with heme pigments: E620(corrected) ¼
E620(raw)   (1.426 3 E740(raw) þ 0.030).
Lung Wet-to-Dry Weight Ratio
Mouse lung wet-to-dry weight ratio (W/D ratio) was used to
measure lung water accumulation after Ang-2 injection. Lung
wet weight was determined immediately after removal of the
right lung. Lung dry weight was determined after the lung
had been dried in an oven at 50 8C for 24 h. The W/D ratio
was calculated by dividing the wet weight by the dry weight.
Histology
Adult mice were injected with 0, 10, or 20 lg of Ang-2
intraperitoneal and sacriﬁced at time zero, 3 h, and 48 h after
injection. Lungs were harvested, ﬁxed in 10% formalin,
embedded in parafﬁn, sectioned, and stained with hematox-
ylin and eosin.
Western Blot Analysis
Cells were washed with ice-cold PBS three times and lysed
with ice-cold RIPA buffer (50 mM Tris-HCl [pH 7.4], 150 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 1
mM EDTA) supplemented with protease inhibitors (Roche
Diagnostics, Indianapolis, Indiana, United States) and 1 mM
NaF. Lysates were sonicated and centrifuged at 10,000 rpm
for 10 min at 4 8C, and supernatants were collected. Protein
concentrations were determined by Bradford protein assay
with bovine serum albumin as a standard (Bio-Rad, Hercules,
California, United States). A mixture of lysate, NuPAGE
reducing agent, and NuPAGE sample buffer were heated at 70
8C for 10 min, electrophoresed in NuPAGE 4%–12% Novex
Bis-Tris Gels (all from Invitrogen Life Technologies, Franklin
Lakes, New Jersey, United States), transferred to polyvinyli-
dene diﬂuoride (PVDF) membrane, and immunoblotted with
speciﬁc primary antibodies. Binding of primary antibodies
was detected using horseradish peroxidase-conjugated sec-
ondary antibodies (Amersham Pharmacia Biotech, Piscat-
away, New Jersey, United States) and SuperSignal WestDura
(Pierce Biotechnology, Rockford, Illinois, United States)
reagents as chemiluminescence substrates. Primary anti-
bodies were obtained from these suppliers: anti-Tie2 anti-
body (clone Ab33) was from Upstate Cell Signaling Solutions
(Lake Placid, New York, United States); anti-GAPDH mono-
clonal antibody was from Chemicon International (Temecula,
California, United States).
Immunoprecipitation
For immunoprecipitation of proteins from total cell
lysates, we lysed cells with RIPA buffer, adjusting protein
concentration by Bradford protein assay (Bio-Rad, Hercules,
California, United States) and incubated 200 lg of total
protein with anti-Tie2 antibody for 3 h, followed by
incubation with protein A sepharose (Zymed, San Francisco,
California, United States) for 2 h at 4 8C. After washing the
beads, proteins were eluted by heating in SDS-sample buffer
and detected by Western blot analysis with Anti-phospho-
tyrosine (clone 4G10, Upstate Cell Signaling Solutions,
Charlottesville, Virginia, United States) as described before.
MLC-p
After signal starvation with 0.25% FBS EBM-2 for 24 h, cells
were treated with100 ng/ml Ang-2 orvehicle for 0,1,3,and 6 h.
MLC-p phospho-serine 19 and GAPDH were detected by
Westernblotanalysis.ForMLC-passaysconductedonHMVECs
treated with serum from patients, serum Ang-2 concentration
was ﬁrst measured by ELISA. Then, serum was diluted to 5%
with EBM-2 and ﬁltered with low-protein-binding PVDF
membrane (0.22 lm, Millipore, Bedford, Massachusetts, United
States). Anti-MLC-phospho-serine-19 Ab was obtained from
Abcam (Cambridge, Massachusetts, United States).
Rho Activity Pull-Down Assay
RhoA activity assay was performed and quantiﬁed using the
RhoA activation assay kit according to the manufacturer’s
instructions (Cytoskeleton, Denver, Colorado, United States).
After signal starvation with 0.25% FBS EBM-2 for 24 h, cells
were treated with 100 ng/ml Ang-2 or vehicle for the indicated
times (0, 30 min, 1 h, 3 h, and 6 h) and harvested into the lysis
buffer. Following a brief centrifugation to remove cell debris,
lysates from control and Ang-2-treated cells containing
equivalent protein concentrations were rotated for 60 min
with a 40-ll slurry of a GST-fusion protein composed of the
Rho-binding domain of the speciﬁc RhoA effector rhotekin
coupled to agarose beads. Beads were collected by centrifu-
gation and washed three times with the lysis buffer. Beads
were then re-suspended in NuPAGE reducing agent and
NuPAGE sample buffer and heated at 70 8C for 10 min. The
liquid phase was electrophoresed in NuPAGE 4%–12% Novex
Bis-Tris Gels (Invitrogen Life Technologies). Whole-cell
lysates from both control and Ang-2-treated cells were also
run to determine baseline levels of total RhoA protein.
Separated proteins were transferred to nitrocellulose and
immunoblotted with a monoclonal antibody to RhoA (Santa
Cruz Biotechnology, Santa Cruz, California, United States).
Immunofluorescence
HMVECs were grown to conﬂuence on glass coverslips
coated with 1% gelatin. The cells were ﬁxed for 10 min in 4%
paraformaldehyde in PBS, and incubated for 5 min in 0.5%
Triton X-100 in PBS. After blocking, the monolayers were
processed for staining with anti-VE-cadherin monoclonal
antibody (BD Biosciences Pharmingen, San Diego, Caliﬁor-
nia, United States) and Alexa Fluoro 488 goat anti-mouse IgG,
rhodamine phalloidin (Molecular Probes, Eugene, Oregon,
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ular Probes) for nuclear staining. Fluorescence images were
obtained using a Bio Rad MRC confocal ﬂuorescence micro-
scope. For experiments using cells treated with serum from
patients, serum Ang-2 concentration was ﬁrst measured by
ELISA. Then, patient serum was diluted to 10% with EBM-2
and ﬁltered with low-protein-binding PVDF membrane (0.22
lm, Millipore) prior to application on EC monolayers.
Measurement of Endothelial Permeability In Vitro
HMVEC monolayer permeability was determined with the
use of FITC-labeled bovine serum albumin (Sigma) as
described elsewhere [22]. Coster Transwell membranes
(Corning, Corning, New York, United States) were coated
with ﬁbronectin, and cells were grown until conﬂuence.
Vehicle or Ang-2 (400 ng/ml) with FITC-albumin (ﬁnal
concentration 1mg/ml) was added to the luminal chamber
for 8 h, and samples were taken from both the luminal and
abluminal chamber for ﬂuorometry analysis. The readings
were converted with the use of a standard curve to albumin
concentration. These concentrations were then used in the
following equation to determine the permeability coefﬁcient
of albumin (Pa):
Pa ¼
½A 
t
3
1
A
3
V
½L 
where [A] is abluminal concentration; t is time in seconds; A is
area of membrane in cm
2; V is volume of abluminal chamber;
and [L] is luminal concentration.
siRNA Transfection of ECs
HMVECs were seeded on 10-cm dishes for Western blot (or
on 1% gelatin-coated coverslips for immunohistochemistry
experiments) 24 h before experiments. 20 lmol of validated,
annealed short interfering RNA (siRNA) (Ambion, Austin,
Texas, United States) directed to human Tie-2 was trans-
fected using silentFect Lipid reagent (Bio-Rad) according to
the manufacturer’s instructions. Cells were used for experi-
ments 3 d after transfection. Down-regulation of Tie-2
receptor was veriﬁed by Western blotting with anti-Tie-2
polyclonal antibody (Upstate Cell Signaling Solutions).
Statistical Analysis
Results are reported as mean 6 standard error of the
mean. Comparisons between continuous variables were
performed using an unpaired two-sided t-test.
Results
Circulating Ang-2 Is Elevated in Patients with Sepsis Who
Have Poor Gas Exchange
Table 1 presents baseline characteristics of the 22 patients
with sepsis enrolled in this initial case cohort over a 2-mo
period (September 2004 to October 2004). A control cohort
of 29 patients was also selected randomly from individuals
hospitalized on the general medical service with a variety of
illnesses over this same time period. Serum specimens were
collected prospectively along with relevant clinical data (see
Methods for enrollment criteria, specimen handling, repro-
ducibility of measurements, and specimen storage). Circulat-
ing Ang-1 was not different between cases and controls
(unpublished data), but Ang-2 at the time of enrollment
(Figure 1) was 23.2 6 9.1 ng/ml among patients with severe
sepsis—deﬁned by the presence of shock or multi-organ
Table 1. Baseline Characteristics of Sepsis Cohort
Characteristic Value
Number of patients 22
Age (y) 69.1 6 15.3
Female sex 11 (50%)
a
Survival to discharge 16 (73%)
APACHE II score 21.2 6 5.3
Portal of entry
Lung 6 (27%)
GU 5 (23%
Catheter 3 (14%)
Abdominal 4 (18%)
Other 2 (9%) foot; 1(5%) endocarditis;
1(9%) unknown
Maximum number of vasoactive agents used
at any one time during hospitalization
0 6 (27%)
1 7 (32%)
2 6 (27%)
3 3 (14%)
Prior/co-morbid conditions
Coronary artery disease 8 (36%)
Diabetes mellitus 9 (41%)
Liver disease 2 (9%)
COPD/asthma 6 (27%)
Cancer 7 (32%)
ESRD 6 (27%)
a(%) reflects percent of sepsis cohort.
DOI: 10.1371/journal.pmed.0030046.t001
Figure 1. Serum Ang-2 at Study Enrollment
Ang-2 was measured in serum specimens obtained prospectively from
patients meeting criteria for sepsis (n ¼ 22) and from randomly selected
hospitalized patients (n¼29), used as a control, with a variety of illnesses
ranging from infectious (e.g., pyelonephritis, aseptic meningitis, pneu-
monia) to cardiovascular (e.g., angina, syncope) and neurologic (e.g.,
stroke) diseases. Patients with sepsis were further subdivided into those
with severe sepsis—defined by the presence of shock or multi-organ
dysfunction (n ¼ 17)—and those without severe sepsis (mild sepsis, n ¼
5). Individuals who were controls (marked Controls) and individuals with
sepsis without shock or multi-organ dysfunction (marked Mild Sepsis)
had low serum Ang-2 at enrollment (3.5 6 0.6 ng/ml and 4.8 6 1.5 ng/
ml, respectively). Patients hospitalized with severe sepsis (marked Severe
Sepsis) had significantly higher serum Ang-2 at enrollment (23.2 6 9.1
ng/ml, p¼0.0071) compared with control patients. During the course of
the hospitalization, only the severe sepsis group had higher peak Ang-2
(32.4 6 8.7 ng/ml), whereas those patients in the control group and
those patients with mild sepsis maintained stable Ang-2 , 10 ng/ml
(unpublished data).
DOI: 10.1371/journal.pmed.0030046.g001
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Ang-2 in Pulmonary Vascular Leakdysfunction (third bar, n¼17)—compared with only 3.5 6 0.6
ng/ml among non-septic hospitalized controls (ﬁrst bar, n ¼
29, p¼0.0071) and 4.8 6 1.5 ng/ml among patients with sepsis
but who did not have shock or multi-organ dysfunction
(second bar, n ¼ 5).
Serial measurements of Ang-2 revealed that the group of
individuals with severe sepsis—the one that started with the
highest circulating Ang-2—developed even higher peak Ang-
2 during the course of hospitalization (32.4 6 8.7 ng/ml),
whereas hospitalized patients who did not have sepsis
(controls) and patients who had sepsis but were without
shock or multi-organ dysfunction (mild sepsis) had Ang-2
serum levels that generally remained  10 ng/ml. Our control
values for serum Ang-2 concentration are consistent with
data reported by others [23].
Serum from Patient CH (Figure 2, —&—) shows a typical
trend of Ang-2 values in a patient with septic shock who
subsequently convalesced and was discharged. This patient
grew enterococcus from her urine and initially required three
vasoactive agents and ventilatory support to manage shock
and hypoxemia. The high peak of Ang-2 followed by
progressive decline to normal values mirrored the course of
her illness. Patient AP’s (Figure 2, —m—) Ang-2 trend was
typical for patients who were hospitalized without sepsis.
Patient AP was an elderly woman admitted to the general
medicine service with an infection, but without evidence of
sepsis. On the other hand, Patient AG’s (—*—) trend is
illustrative of Ang-2 values both during a non-sepsis-related
hospitalization (left of break line) as well as a later hospital-
ization (right of break line) during which the patient died
from complications of severe sepsis. Patient AG was ﬁrst
hospitalized for hypotension following excessive ﬂuid remov-
al during dialysis without evidence of infection, systemic
inﬂammatory response, or respiratory compromise (Figure 2,
to the left of the broken line, depicted as hospital days 1–3).
During this time, his Ang-2 remained ﬂat and ,10 ng/ml.
However, 3 mo later, he was re-hospitalized for emergent
lower leg amputation to treat gangrene and severe sepsis (to
the right of the broken line, depicted as hospital days 6–8 for
purposes of illustration). This second admission was associ-
ated with abruptly rising Ang-2—the last measurement was
made on the day of his death despite aggressive measures in
the intensive care unit. The rising Ang-2 curve associated
with Patient AG’s death was typical of patients with severe
sepsis who died despite aggressive measures.
Given our hypothesis that Ang-2 imbalance should prefer-
entially affect lung permeability—where Tie-2 expression is
highest [19]—we compared peak circulating Ang-2 value
during hospitalization between individuals with very poor
oxygenation versus those with less impaired oxygenation.
PaO2/FiO2, the ratio of arterial blood’s oxygen partial
pressure (PaO2) to the fraction of inspired air consisting of
oxygen (FiO2) [24], was used as a metric to assess the defect in
oxygen absorption from the lung into the bloodstream. A
cutoff of 200 in the PaO2/FiO2 ratio was used to segregate
groups into more and less severe impairment in gas exchange
because it is one of the diagnostic criteria for ARDS [5].
Indeed, Ang-2 did correlate strongly with nadir impairment
in gas exchange—41.95 6 12.44 ng/ml among those patients
with PaO2/FiO2 , 200 versus 11.22 6 2.44 ng/ml in the group
of individuals with better oxygenation (PaO2/FiO2 . 200); p¼
0.02 (Figure 3A). Ang-2 did not correlate with survival to
discharge nor to level of critical illness at enrollment as
deﬁned by APACHE II (acute physiology and chronic health
evaluation) (Figure 3B and 3C). Ang-2 also did not correlate
with a history of congestive heart failure (Figure 3D). There
was also no correlation of Ang-2 with an underlying history of
lung disease, renal failure, or cancer (unpublished data). Of
note, the one patient in our cohort who did meet full criteria
for ARDS had Ang-2 ¼ 139 ng/ml, the highest level measured
in our group. Circulating Ang-2 elevation, therefore,
appeared to correlate speciﬁcally with a low PaO2/FiO2 ratio.
Serum from Patients with Sepsis Disrupts Endothelial
Architecture, an Effect that Resolves with Clinical
Convalescence, Correlates with Ang-2, and Is Reversed by
Ang-1
Separation of adjacent ECs from one another leads to
paracellular gap formation—a process driven by actin–
myosin-based cell contraction [25–27]. Such gaps permit
para-endothelial movement of macromolecules and, thus,
represent a structural change that correlates with hyper-
permeability. To test what structural effect human serum had
on cultured ECs, we added serum from two patients, Patient
CE4 (high Ang-2) and Patient CF1 (low Ang-2), to HMVECs
and stained for F-actin and VE-cadherin, a structural protein
that helps maintain intercellular junctions. Incubation of
HMVECs with control medium (FBS/culture medium) re-
sulted in a compact, conﬂuent cell layer with thin actin
ﬁlaments and localization of VE-cadherin to cell–cell junc-
Figure 2. Temporal Trends of Circulating Ang-2 in Three Illustrative
Hospitalized Patients
Patient CH (—&—), a 74-y-old woman, was admitted to the medical
intensive care unit with severe sepsis. She was treated with broad-
spectrum antibiotics, initially required three vasoactive agents to manage
shock, and was mechanically ventilated. Patient CH’s nadir PaO2/FiO2 ¼
240 occurred on hospital day 2, correlating with her peak circulating Ang-
2. Enterococcus was grown from her urine. She progressively convalesced
and was extubated prior to discharge. Patient AP (—m—), a 92-y-old
woman, was admitted to the general medicine service from a nursing
home for increased confusion over her baseline dementia. She had no
evidence of sepsis, shock, or respiratory compromise—PaO2/FiO2 . 300.
She was treated for a foot wound infection with two antibiotics and was
discharged in stable condition back to the nursing home. Patient AG
(—*—), a 77-y-old man, was first admitted to the general medicine
service with hypotension following excessive fluid removal at hemodial-
ysis—there was no evidence of infection, systemic inflammatory
response, or respiratory compromise with PaO2/FiO2 . 300 (hospital
days1–3). However, 3 molater(graphedas hospitaldays 6–8for purposes
of illustration), the same patient (—*—) was re-admitted to the intensive
care unit following emergent right leg amputation for gangrene
complicated by shock and inability to extubate. Nadir PaO2/FiO2 ¼ 144
occurred on the same day as peak Ang-2 (depicted as hospital day 8),
when he died despite full care.
DOI: 10.1371/journal.pmed.0030046.g002
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(CE4, Ang-2 ¼ 89 ng/ml) induced thick actin stress ﬁbers and
intercellular gap formation (Figure 4D–4F, arrows) whereas
low Ang-2 serum (CF1, Ang-2¼8.9 ng/ml) did not (Figure 4G–
4I). The gap formation provoked by the serum from Patient
CE4 was reversed with addition of recombinant human Ang-1
(Figure 4J–4L).
To address the potential biasing effect of unmeasured
confounders between sera from two different patients, we
repeated this experiment with serum from one patient taken
at two time points during his hospitalization. Serum from
Patient CG was collected on hospital day 2 (CG2, Ang-2 ¼ 78
ng/ml), and on hospital day 16 (CG12, Ang-2 ¼ 6.3 ng/ml). On
hospital day 2, Patient CG had PaO2/FiO2 ¼ 56, was in septic
shock, and had ARDS; by hospital day 16, Patient CG was
extubated, convalescing uneventfully and preparing for
discharge. Serum from CG’s hospital day 2 (Figure 4, CG2)
induced gap formation and thick actin stress ﬁbers (Figure
4M–4O), effects not seen with his serum at discharge (Figure
4P–4R, CG12); moreover, effects of high Ang-2 serum from
hospital day 2 (Figure 4, CG2) were reversed with the addition
of Ang-1 (Figure 4S–4U).
These results illustrate (a) the presence of a serum
activity during severe sepsis that induces endothelial
barrier disruption; (b) that clinical resolution correlates
with falling Ang-2 and decreased barrier-disrupting activity;
and (c) that this activity can be reversed with Ang-1,
suggesting that Ang-2 in the serum of human patients is at
least partially responsible for altering endothelial architec-
ture in sepsis.
Ang-2 Alone Replicates the Effect of Serum from Patients
with Sepsis on Endothelial Structure and Promotes
Endothelial Hyperpermeability
Having observed this effect of serum from human patients
on cultured ECs, we next tested whether Ang-2 alone could
reproduce disruption of endothelial architecture. Recombi-
nant human Ang-2 (100 ng/ml) was added to HMVECs, which
were subsequently stained for F-actin and VE-cadherin. As
suspected, Ang-2 induced the formation of thick actin stress
ﬁbers and intercellular gaps (Figure 5Ad–5Af, arrows), effects
not seen with vehicle incubation (Figure 5Aa–5Ac). This
experiment conﬁrmed the hypothesis raised by the results in
Figure 4—namely that Ang-2 alone could provoke potentially
pathologic structural changes in endothelium.
After establishing that Ang-2 could promote pathologic
structural changes in endothelial monolayers, we next asked
whether Ang-2 could modulate barrier function. To deter-
mine the effect of Ang-2 on monolayer permeability, we
monitored the clearance of FITC-labeled albumin across an
HMVEC monolayer with and without Ang-2 stimulation.
Figure 5B shows that Ang-2 stimulation for 8 h increased
permeability by approximately 20% compared with the
control (p , 0.01).
The Effect of Ang-2 on Endothelial Architecture Is
Mediated by Rho-Kinase and MLC-p
Since Ang-2 appeared to be a likely mediator of endothelial
barrier disruption in serum from humans with sepsis, we next
sought to understand the intracellular mechanism through
which Ang-2 could distort endothelial shape and cell–cell
contacts.
Figure 3. Peak Circulating Ang-2 Correlates with Impaired Pulmonary
Gas Exchange
(A) Impaired oxygenation of blood, as assessed by the nadir PaO2/FiO2
ratio, correlates with significant differences in circulating Ang-2, *p ¼
0.0195.
(B) Circulating Ang-2 does not correlate with survival to discharge.
Among the five patients who did not survive, medical care was
withdrawn from three patients in accordance with family wishes; the
remaining two died despite full measures.
(C) APACHE II is a commonly used scoring system to rate overall severity
of critical illness. Ang-2 does not differ significantly among individuals
with high (more severe illness) or low (less severe illness) APACHE II
scores.
(D) History of congestive heart failure (defined by clinical documentation
in medical record of measured ejection fraction ¼ , 40%) does not
correlate with significant differences in circulating Ang-2.
DOI: 10.1371/journal.pmed.0030046.g003
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by myosin-driven cellular contraction [8,28–30]. For contrac-
tion to occur, MLC must be phosphorylated at Ser-19 by EC
MLCK, and phosphorylation of Ser-19 by EC MLCK is needed
to activate actomyosin ATPase function [31,32]. We therefore
hypothesized that Ang-2 up-regulated MLC-p.
Initially, we tested the effect of serum from humans with
sepsis on MLC-p. Serum was taken from the same patients
used for immunohistochemistry in Figure 4D–4I—CE2 (Ang-
2¼77 ng/ml) and CF5 (Ang-2¼7.9 ng/ml)—and added at 1:20
dilution to 24-h serum-starved HMVECs. The high Ang-2
serum (CE2) caused MLC-p that was inhibited by addition of
Ang-1, whereas the low Ang-2 serum led to markedly less
MLC-p (Figure 6A).
Next, we tested the effect of Ang-2 alone (100 ng/ml) on 24-
h serum-starved HMVECs at serial time points. We observed
Figure 4. Serum from People with Sepsis Disrupts Endothelial Architecture and This Effect Resolves with Clinical Improvement, Correlates with
Measured Ang-2, and Is Reversed by Ang-1
Ten percent FBS or 10% serum from one of two patients with sepsis was incubated with EC monolayers to assess effects on endothelial architecture.
High Ang-2 serum (Patient CE4, Ang-2 ¼ 89 ng/ml) induced thick actin stress fibers and intercellular gap formation (D–F), whereas low Ang-2 serum
(CF1, Ang-2¼8.9 ng/ml) did not (G–I). The gap-promoting effect of Patient CE49s serum was reversed with addition of 100 ng/ml recombinant human
Ang-1 (J–L) and was indistinguishable from control cells that exhibit thin actin fibers and no intercellular gaps (A–C).
Serum was then taken from one patient (Patient CG), drawn on hospital day 2 (Patient CG2, Ang-2¼78 ng/ml) and hospital day 16 (Patient CG12, Ang-2
¼6.3 ng/ml), and was added at 10% to HMVEC monolayers. Again, high-Ang-2 serum (CG2) induced gap formation and thick actin stress fibers (M–O),
effects not seen in the serum of the same patient at discharge (CG12) (P–R) and effects that were reversed with the addition of 100 ng/ml Ang-1 (S–U).
Arrows indicate intercellular gaps.
DOI: 10.1371/journal.pmed.0030046.g004
PLoS Medicine | www.plosmedicine.org March 2006 | Volume 3 | Issue 3 | e46 0362
Ang-2 in Pulmonary Vascular Leakthat MLC-p was elevated at 3 h and 6 h of stimulation (Figure
6B) and persisted for 24 h (unpublished data).
Rho-GTPases play a pivotal role in the control of cellular
actin rearrangement and cell shape [33]. Rho-kinase, a
downstream target of RhoA, stimulates stress ﬁber formation
by up-regulating MLC-p through two mechanisms: activation
of EC MLCK and inhibition of myosin phosphatase activity
[34,35]. Given this 2-fold effect of RhoA on MLC, one would
predict that a RhoA inhibitor would be even more potent
than an MLCK inhibitor at blocking MLC-p. We asked if Ang-
2-induced MLC-p required activated RhoA. We tested this
possibility by treating 24-h-serum-starved HMVECs with Ang-
2 (100 ng/ml) for different time periods (0, 30 min, 1 h, 3 h,
and 6 h) and then by measuring RhoA activation. Indeed,
Ang-2 induced an increase in the active form of RhoA (Rho-
GTP) (Figure 6C) that peaked between 30 min and 1 h. Pre-
treatment of Ang-2-stimulated HMVECs with a speciﬁc
inhibitor of Rho-kinase (Y27632, 10 lM) completely abolished
Ang-2-induced MLC-p (Figure 6D, third column) while an EC
MLCK inhibitor (ML-7, 10lM) partially inhibited MLC-p
(Figure 6D, fourth column). These results demonstrate that
Ang-2 mediates MLC-p in a RhoA-dependent fashion in
human microvascular ECs.
Given that Ang-2 induces gap formation between ECs
(Figure 5) and that Ang-2 stimulates MLC-p through Rho-
kinase (Figure 6B–6D), we next asked whether Ang-29s gap-
formation effect occurred through Rho-kinase and MLCK.
Y27632 (10 lM) completely reversed the formation of thick
actin stress ﬁbers and paracellular gaps induced by Ang-2
(Figure 6Ea–6Ef). ML-7 (10 lM) partially reversed the Ang-2-
induced structural changes on actin and cell junctions (Figure
6Eg–6Ei), consistent with the less potent effect of ML-7 versus
Y27632 on MLC phosphorylation (Figure 6D). These results
demonstrate that the deleterious structural effects of Ang-2
on ECs are mediated through Rho-kinase and MLCK.
Tie-2 Knock-Down Replicates the Ang-2-Induced
Endothelial Barrier Disruption
Multiple lines of evidence suggest that Ang-1 and Ang-2 are
an agonist–antagonist pair at the Tie-2 receptor [36]. Ang-1
activates Tie-2, leading to receptor phosphorylation and
subsequent signal transduction that promotes EC survival and
vessel assembly. Ang-2, on the other hand, is believed to act as
a Tie-2 ligand that competitively binds the receptor and
interferes with agonistic Ang-1/Tie-2 functions—i.e., Ang-2
binding of Tie-2 blocks Tie-2 phosphorylation. To further
Figure 5. Ang-2 Alone Disrupts Endothelial Architecture at Physiologic Concentrations
(A) Control (vehicle) or recombinant human Ang-2 (100 ng/ml) was added to HMVEC monolayers. These cells were then fixed and stained for F-actin
and VE-cadherin. Shown are healthy control cells (panels a–c) versus Ang-2 treated cells (panels d–f), which exhibit thick actin stress fibers and disrupted
junctions, leaving intercellular gaps (arrows).
(B) HMVECs were grown to confluence on Transwell membranes coated with fibronectin. Monolayers were treated with vehicle or Ang-2 (400 ng/ml in
luminal chamber) plus FITC-albumin. Pa was calculated after 8 h as described in the Methods section. Pa values are expressed as percentage of control
cells.*p , 0.01.
DOI: 10.1371/journal.pmed.0030046.g005
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contraction and gap formation, we ﬁrst conﬁrmed that Ang-2
(100 ng/ml) inhibited phosphorylation of Tie-2 receptor in
HMVECs (Figure 7A).
We then assessed the effect of Tie-2 signaling on MLC-p by
using siRNA against Tie-2 receptor (Tie-2-siRNA). Tie-2-
siRNA induced robust MLC-p (Figure 7B, middle blot),
recalling the effect seen with Ang-2 treatment (Figure 6B).
Figure 6. Ang-2 Disrupts Endothelial Architecture by Upregulating MLC-p in an MLCK- and Rho-Kinase–Dependent Fashion
(A) Serum was taken from two patients—Patient CE2 (Ang-2¼77 ng/ml) and Patient CF5 (Ang-2¼7.9 ng/ml)—and added at 20-fold dilution to 24-h
serum-starved HMVECs. High Ang-2-serum (Patient CE2) caused MLC phosphorylation that was diminished by addition of Ang-1 (100 ng/ml), whereas
low Ang-2-serum (CF5) did not induce MLC phosphorylation.
(B) After 24-h serum starvation, Ang-2 (100 ng/ml) was added to HMVECs, and cells were lysed at the indicated times. MLC-p was determined by
Western blot as described in the Methods section. MLC-p was elevated at 3 h and 6 h of stimulation.
(C) After 24-h serum starvation, Ang-2 (100 ng/ml) was added to HMVECs, and cells were lysed at the indicated times. GTP-RhoA was pulled down and
blotted as described in the Methods section. GTP-RhoA peaked at 30–60 min of Ang-2 stimulation.
(D) After 24-h serum starvation, HMVECs were stimulated with Ang-2 (100 ng/ml) with or without 10 lM Y27632 (Rho-kinase inhibitor) or 10 lM ML-7
(MLCK inhibitor) for 5 h. MLC-p was determined by Western blot as described in the Methods section. Y27632 had a more potent inhibitory effect on
MLC-p than equimolar ML-7.
(E) HMVECs were grown to confluence and incubated for 5 h with Ang-2 (100 ng/ml) (panels a–c). HMVECs were also stimulated with Ang-2 (100 ng/ml)
in the presence of 10 lM Y27632 (panels d–f) or 10 lM ML-7 (panels g–i). Cells were fixed and stained for F-actin and VE-cadherin as described in the
Methods section. Shown are representative confocal fluorescence microscopy images (6003). Ang-2 provokes stress fibers within cells (panel a) and gap
formation between cells (panel c, arrows). These changes are reversed by co-incubation with Y27632 or ML-7. F-actin, panels a, d, and g; VE-cadherin,
panels b, e, and h; merge images, panels c, f, and i.
DOI: 10.1371/journal.pmed.0030046.g006
PLoS Medicine | www.plosmedicine.org March 2006 | Volume 3 | Issue 3 | e46 0364
Ang-2 in Pulmonary Vascular LeakTie-2-siRNA caused a spindle phenotype (Figure 7Ce), thick
actin stress ﬁbers and paracellular gap formation (Figure
7Cf–7Ch, arrows), effects not observed with negative control
siRNA transfection (Figure 7Ca–7Cd). These morphologic
changes are on the same spectrum as, but even more severe
than, those seen with the addition of Ang-2 (Figure 5Ad–5Af).
These results suggest that Tie-2 signaling is constitutively
active in this system. Addition of Ang-2 blocks Tie-2 signal-
ing, leading, in turn, to Rho-kinase activation and MLC-p,
with the end result being EC contraction, gap formation, and
disruption of barrier integrity.
Systemic Administration of Ang-2 Provokes Vascular
Hyperpermeability and Pulmonary Congestion in Healthy
Adult Mice
So far, we had identiﬁed Ang-2 as an important circulating
factor in serum from humans with sepsis that distorts the
endothelial barrier, and we had determined that this action
was carried out by Tie-2 blockade and activation of Rho-
kinase and MLCK. To establish the functional importance of
maintaining this barrier, we hypothesized that systemic
administration of Ang-2 would provoke pulmonary vascular
hyperpermeability and congestion.
Figure 7. Tie-2 Knock-Down Inhibits MLC-p and Promotes Disrupted Endothelial Architecture, Replicating the Effects of Ang-2
(A) HMVECs were stimulated with Ang-2 (100 ng/ml) in 2.5% FBS EBM-2 for the indicated times, and phospho-Tie-2 was detected by
immunoprecipitation and Western blot (upper) as described in Methods. Similar amounts of total Tie-2 were present in HMVECs harvested at each time
point. Phospho-Tie-2 declined over time whereas total Tie-2 remained relatively constant (lower).
(B) Negative control siRNA (left column) or a Tie-2-specific siRNA (right column) was transfected in HMVECs. Cells were then serum-starved for 24 h, after
which decreased Tie-2 expression (right column, upper blot) and increased MLC phosphorylation (right column, middle blot) were verified with Tie-2
siRNA.
(C) Phase contrast (2003) and fluorescence images (6003) of cells stained for F-actin and VE-cadherin after transfection of negative control siRNA (panels
a–d) or Tie-2 specific siRNA (panels e–h). Tie-2-siRNA caused thick actin stress fibers and gap formation in HMVECs (panel h, arrows). Phase contrast
images, panels a and e; F-actin, panels b and f; VE-cadherin, panels c and g; merge images, panels d and h.
DOI: 10.1371/journal.pmed.0030046.g007
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Ang-2 in Pulmonary Vascular LeakEvans blue avidly binds to serum albumin and can
therefore be used as a tracer for trans-capillary ﬂux of
macromolecules. The extravasation of Evans blue has
frequently been employed to quantify in vivo vascular
permeability [37,38]. Given the several limitations of in vitro
permeability assays—e.g., lack of ﬂow and variable hydrostatic
pressure, use of cultured cells, absence of microenvironment,
and absence of interacting cell types such as neutrophils
[39]—we felt that it was important to conﬁrm leak across
intact blood vessels in an in vivo setting. Adult mice were pre-
treated with either vehicle or Ang-2 (10 lg) injected intra-
peritoneally prior to Evans blue dye injection. Although no
mice in either group exhibited any signs of sickness (e.g.,
motionlessness, piloerection, diarrhea) 16 h after treatment,
spectrophotometric quantiﬁcation of extravasated dye
showed enhanced leakage, with a 3-fold increase in lungs
and a 2-fold increase in livers of Ang-2-treated mice
compared with vehicle-treated mice (Figure 8A) (p , 0.01).
Intestines were also tested and showed a statistically non-
signiﬁcant trend toward increased permeability (Figure 8A).
After washout of intravascular Evans blue by perfusing PBS
through the right ventricle and venting from the vena cava,
lungs of vehicle-treated mice were blanched-appearing
(Figure 8B, left panel); however, lungs of Ang-2-treated mice
appeared more congested and purple-tinted (Figure 8B, right
panel), suggesting retention of dye in the extravascular space.
In addition, the lung W/D weight ratio increased from 5.01 6
0.26 to 6.13 6 0.03 with Ang-2 treatment (Figure 8C) (p ,
0.01), suggesting increased lung water accumulation following
Ang-2 administration.
Lung sections were also taken for histologic character-
ization. Figure 9A shows lung from a control mouse injected
with vehicle—alveolar septa form a ﬁne, thin network (inset
on lower right). 3 h after systemic Ang-2 administration (10
lg), there is an increase in cellularity, congestion, and early
extravasation into air spaces (Figure 9B). These changes are
even more pronounced at 48 h (Figure 9C) following a total
Ang-2 dose of 20 lg. These results establish an in vivo
causative role for Ang-2 in pulmonary vascular leak and
further substantiate the in vitro permeability effects observed
earlier with Ang-2 stimulation (Figure 5). Moreover, pro-
gressive lung injury appears to occur with increasing amount
and duration of systemic Ang-2 exposure.
Discussion
Our results support the hypothesis that Ang-2 is a
mediator of pathologic vascular leak in the lung. We show
that Ang-2 elevation in patients with sepsis correlates with
impaired oxygenation. We demonstrate that the ability of
serum from humans with sepsis to disrupt endothelial
architecture correlates with Ang-2 level, improves with
clinical convalescence, and is reversed by Ang-1. We show
that Ang-2 is not simply a marker in severe sepsis, but that it
has a causative role in disturbing endothelial architecture.
We elucidate this causal role for Ang-2 by identifying an
intracellular mechanism linking Ang-2 to MLC-p. Last, we
administer Ang-2 to healthy mice and induce severe
pulmonary vascular leak and congestion. These results
collectively argue that elevated circulating Ang-2 occurs in
severe sepsis and that excess Ang-2 can produce pulmonary
hyperpermeability in vivo.
Vascular leak has been difﬁcult to assess routinely in the
clinical setting because there are no widely applicable tools to
measure this process—imaging of extravasated radiolabeled
macromolecules is primarily a research tool [40–44]. Despite
this limitation, endothelial hyperpermeability has been
identiﬁed as an important early pathophysiologic contributor
Figure 8. Systemic Administration of Ang-2 Promotes Pulmonary
Hyperpermeability and Water Accumulation
(A) After injection of vehicle or Ang-2 (10 lg, intraperitoneal), mice were
injected in the retro-orbital sinus with Evans blue (2%, 50 ll); after
sacrifice, intravascular Evans blue was washed out with PBS and vascular
leakage was evaluated by measuring extravasated Evans blue. The
amount of Evans blue in organ homogenates was spectrophotometri-
cally quantified. Evans blue content significantly increased in the lung
and liver of Ang-2–treated mice, indicating leakage out of the
vasculature and impregnation within the tissue, *p , 0.01.
(B) Representative photographs of lungs were taken after washout of
intravascular Evans blue with PBS for 10 min. The lung from a control
(vehicle intraperitoneal) mouse (left) appears blanched in contrast to the
purple-tinted, congested lung from an Ang-2-treated mouse (right).
(C) The lung W/D weight ratio was determined as described in the
Methods section. Ang-2 treatment for 16 h increased lung W/D weight
ratio, consistent with congestion due to water accumulation, *p , 0.01.
DOI: 10.1371/journal.pmed.0030046.g008
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Ang-2 in Pulmonary Vascular Leakto the development of ARDS and acute lung injury [24]. The
particular susceptibility of the lung to vascular leak has not
been adequately understood. From a purely physiological
standpoint, the low hydrostatic pressures in the pulmonary
vascular tree should actually mitigate ﬂuid extravasation.
However, given that Tie-2 mRNA and protein are most
abundant in the lung [19,20], we believe that the lung is
uniquely dependent on Tie-2 signaling to maintain the
permeability barrier, and that sepsis provides a model system
in which that signaling is blocked by excess circulating Ang-2.
Though excess systemic Ang-2 provokes extravasation from
and congestion of the pulmonary capillary bed, we have not
deﬁnitively shown that this effect is due only to endothelial
changes. In fact, an intriguing possibility is that excess Ang-2
both distorts microvascular architecture—a conclusion that
can be inferred from our data—but also potentially interferes
with larger vessels by exerting effects on tone that change
hydrostatic pressure to favor extravasation. Such an effect on
tone could occur through endothelial-dependent signaling—
e.g., nitric oxide [45]—or perhaps through direct effects on
smooth muscle itself. For example, it is unknown if smooth-
muscle-lined vessels express ‘‘endothelial-restricted’’ recep-
tors such as Tie-2 in stress states such as sepsis. Such suggested
effects of Ang-2 on muscle cells may even occur in a Tie-2-
independent fashion, as one recent report asserts [46].
Our data point to activation of a signaling system (Rho-
kinase, EC MLCK) upon withdrawal of Tie-2 phosphorylation.
The likeliest explanations for this observation are either (a)
that the activated receptor is sequestering an activator of the
Rho-kinase pathway or (b) that the activated receptor up-
regulates an inhibitor of the Rho-kinase pathway. We are
exploring several candidate mediators that meet these
criteria to bridge this signaling gap. Though the entire
pathway remains to be mapped, there are immediate
therapeutic implications of the data presented here.
MLC-p may represent a ﬁnal common pathway for multiple
provocateurs of vascular leak—TNF-a, IL-1, complement
components—to exert their pathologic pro-permeability
effect [47–49]. Inhibitors along this pathway, such as a RhoA
inhibitor, would be predicted to block vascular leak. Blockade
of one downstream target of RhoA, EC MLCK (by conditional
knock-out and chemical inhibition), has already been shown
to protect mice from endotoxin-mediated lung injury,
further bolstering this hypothesis [30].
Inhibition of EC MLCK may allow clinicians to treat poor
barrier function without direct immunomodulation, as
opposed to blockade of TNF-a, IL-1, or complement proteins,
all of which are interventions that also affect innate and/or
adaptive immunity. Undesired pleiotropic effects, such as
poorly timed immunosuppression, may be one reason why
these therapies have failed in clinical trials for sepsis.
Theoretical advantages of directing therapy to Tie-2 to
prevent, stabilize, or reverse leak conditions such as sepsis
are the lack of global immunosuppression and the expected
restriction of effects to the vasculature, particularly to the
pulmonary vasculature where Tie-2 is most abundantly
expressed. This remains a hypothesis until a clinical trial
demonstrates the beneﬁt in sepsis/ARDS, but one report has
shown a beneﬁcial effect of Tie-2 agonism in a mouse
endotoxin model of shock [50]; another study has shown that
locally elevated Ang-2 can provoke extravasation in the
mouse hind paw [51]. These results independently afﬁrm the
Figure 9. Systemic Ang-2 Administration Provokes Rapid and Progres-
sive Pulmonary Congestion
Ang-2 was administered intraperitoneally (10 lg), and lung sections were
assessed for histologic changes. Control lung is shown at 1003 in (A).
Note the thin alveolar septa, particularly in the inset (4003).
(B) 3 h after Ang-2, there is noticeable expansion of alveolar septa with
increase in cellularity, reduction in air space, and some leakage of cells
into the alveolar space.
(C) These changes are more advanced after 2 d of systemic Ang-2
administration (total dose 20 lg).
DOI: 10.1371/journal.pmed.0030046.g009
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latter to promote vascular leak.
The clinical data presented in Figures 1–3 come from a
pilot cohort of patients with sepsis. Undoubtedly, a larger
study is needed, particularly one that enrolls ARDS patients
who do not have sepsis, to test whether Ang-2 is a valid
biomarker for diagnosis, stratiﬁcation, or prognosis in this
condition. However, despite the small sample size and the
relative wellness of the patients we studied, we were still able
to identify a robust correlation between very poor PaO2/FiO2
ratio and Ang-2 elevation. We observed that peak Ang-2 did
occur at the same time as nadir PaO2/FiO2 ratio, and that
peak Ang-2 followed the most severe stage of illness by ;24 h
(unpublished data). The delayed rise in Ang-2 following the
most severe stage of illness may imply that an angiopoietin-
signaling disturbance occurs as a secondary phenomenon to
release of early-phase cytokines such as TNF-a. But, given that
ARDS due to non-pulmonary causes also classically occurs as
a delayed phenomenon, the later rise in Ang-2 may help
explain why the delay in extra-pulmonary ARDS onset exists.
If Ang-2 is conﬁrmed as a relevant biomarker of acute lung
injury, then it may help to determine prognosis and to stratify
patients, especially in clinical trials to treat ARDS. Given the
rapidity with which Ang-2 rises in severe sepsis (Figure 2,
Patient AG, —*—), it is less likely to be an effective screening
tool if tested only one time several days before onset of
permeability edema in the lungs. On the other hand, if serial
Ang-2 values are followed in at-risk patients, then a rising
slope could identify someone who would particularly beneﬁt
from therapy directed against leak itself in an effort to halt
the evolution of ARDS at its earliest exudative phase.
Our results must be interpreted with caution. We have
shown a correlation between serum Ang-2 and poor gas
exchange in patients with severe sepsis. The correlation may
not be causative, and several alternate possibilities must be
ruled out in future investigations. First, based on the anti-
leakage effect of Ang-1 on mature vasculature [17,52] and the
pro-leakage phenotype we have observed with excess Ang-2,
we believe Ang-2 is acting as a Tie-2 antagonist in the setting
of sepsis as per its initial description [12], but it is worth
remembering that the action of Ang-2 on Tie-2 appears to be
dose-, duration-, and context-speciﬁc in vitro [12,53,54].
Second, Ang-2 release can be driven by inﬂammatory stimuli
such as TNF-a that are clearly present in sepsis, and,
therefore, Ang-2 elevation may represent only an epipheno-
menon without functional signiﬁcance—this is less likely as
our results demonstrate actual pathologic effects, in vitro and
in vivo, of excess Ang-2 alone.
Several additional questions remain to be answered in
future studies. First, as mentioned, Ang-2 is a known hypoxia-
induced gene product [55–57], but its source(s) in sepsis are
unclear. A study of critically ill patients with hypoxia but
without sepsis, such as those with cardiogenic shock, would
help elucidate whether hypoxia alone induces pathologic
elevation in circulating Ang-2.
Second, Ang-2 expression is also up-regulated by vascular
endothelial growth factor (VEGF) and basic ﬁbroblast growth
factor [57]. Interestingly, serum VEGF appears to be elevated
in severe sepsis [58]. VEGF is known to be a pro-permeability
ligand, but it may be that Ang-2 partially mediates VEGF’s
permeability effect; alternatively, VEGF and Ang-2 may be
acting in parallel to provoke vascular leak. However, VEGF
blockade alone did not improve survival in one report
studying a well-accepted rodent model of sepsis [59]. Our
results suggest that excess Ang-2 is sufﬁcient to promote
pulmonary vascular leak and congestion, but pending experi-
ments to block Ang-2 action in sepsis/ARDS models will help
assess the relative contributions of VEGF and Ang-2 to sepsis/
ARDS more deﬁnitively.
Third, pre-formed Ang-2 can be released from ECs
stimulated by inﬂammatory ligands, such as TNF-a [60], or
even released non-speciﬁcally following EC death. What
remains to be determined is what cell type(s) and what
organ(s) account for the elevated Ang-2 level. Apoptosis alone
is unlikely to account for Ang-2 elevation for two reasons: (a)
under conditions in which only limited apoptosis is observed
following in vitro stimulation of ECs with endotoxin,
signiﬁcant up-regulation of Ang-2 is noted (unpublished
data); moreover, (b) endotoxin stimulation in vivo also
appears to result in organ-speciﬁc up-regulation of Ang-2
transcription (unpublished data).
Finally, the reason underlying the lung’s particular suscept-
ibility (as opposed to other organ beds) to ﬂuid extravasation
may be as simple as extra reliance on tonic Tie-2 activation,
but several other endothelial receptor/ligand pairs may also
be involved. More broadly, exploring the impact of the
endothelium in other pulmonary diseases may yield valuable
insights [61]. Disturbances in other members of the angio-
poietin axis—e.g., Ang-4, soluble Tie-2—in ARDS also need to
be explored. Such studies will further deﬁne the role of the
endothelium—as opposed to the epithelium—in defending
the alveolar permeability barrier.
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Background. Sepsis is a severe illness caused by overwhelming infection
of the bloodstream by toxin-producing bacteria. It results from an
infection in one part of the body (such as the lungs or the skin) that has
then spread throughout the body. In developed countries, the number
of deaths due to sepsis has fallen in the past decades. Nevertheless,
about 30% of patients admitted to hospital with sepsis still die from the
disease or the secondary effects of the disease (physicians refer to these
secondary effects as ‘‘complications’’). One of these complications is a
severe medical condition of the lungs called acute respiratory distress
syndrome (ARDS). In ARDS, small blood vessels in the lungs become
leaky and release fluid. This prevents the lungs from doing their job—
that is, taking up oxygen and disposing of carbon dioxide. Patients
experience trouble breathing and usually need to be put on respirators.
If the condition lasts too long, the lung tissue becomes damaged,
sometimes irreversibly. In the past few years, scientists have begun to
understand what keeps blood vessels properly ‘‘sealed.’’ One of the
potential players is a protein called Tie-2, which is present on the surface
of blood vessel cells and affects their behavior. Tie-2 is itself controlled
by a pair of proteins called Ang-1 and Ang-2. When the Ang-1 protein
binds to Tie-2, it switches it on. When the Ang-2 protein binds to Tie-2, it
switches it off.
Why Was This Study Done? The researchers wanted to find out
whether Tie-2, and the Ang-1 and Ang-2 proteins, might play a role in
sepsis and ARDS in humans. In previous research in mice, excess levels of
Ang-1 seemed to make blood vessels less leaky than they normally are,
suggesting that Ang-2 might have the opposite effect. In humans, lungs
have the highest Tie-2 levels of all adult organs, and reduced Tie-2 levels
in the lungs have been found in some infants who died from respiratory
problems.
What Did the Researchers Do and Find? They tested whether excess
levels of Ang-2 occur in sepsis and could cause leakiness of lung blood
vessels in three different ways. First, they measured the level of Ang-2 in
the blood of patients with sepsis. Second, they tested whether blood
from patients with sepsis could cause leakiness in blood vessels grown in
the laboratory. Finally, they tested whether elevated levels of Ang-2
affect the leakiness of blood vessels in the lungs and affect the lungs’
proper functioning in mice. They found that Ang-2 levels are raised in
patients with sepsis, especially in those that have impaired uptake of
oxygen. During the course of the disease, Ang-2 levels mirror a patient’s
condition: they go up as the condition worsens and go down as the
patient gets better. They then showed that treating blood vessels grown
in the laboratory with blood from patients with ARDS made these blood
vessels leaky. They could get the same results by treating the blood
vessels with only Ang-2, and reverse the leakiness by subsequent
treatment with Ang-1. Consistent with a key role of Ang-2 in ARDS, they
found that injecting Ang-2 into the blood of healthy mice caused ARDS-
like symptoms in the mice.
What Does This Mean? These results suggest that Ang-2 might be a key
player in ARDS due to sepsis. The results also suggest that measuring
levels of Ang-2 in a patient might be a way for doctors to assess how
much lung damage there has been in a patient who has developed
ARDS. This new study raises the possibility that reducing Ang-2 levels in
patients might help to prevent or improve ARDS in patients with sepsis.
Additional studies in patients with sepsis, and in patients with ARDS that
is not caused by sepsis, are needed to clarify the roles of Ang-2 and Tie-2
in ARDS and the suitability of Ang-2 as a target for therapy.
Where Can I Find More Information Online? The following Web sites
contain information on ARDS.
The ARDS Support Center:
http://www.ards.org/
MedlinePlus:
http://www.nlm.nih.gov/medlineplus/ency/article/000103.htm
ARDSNet:
http://www.ardsnet.org
Pages from the American Lung Association:
http://www.lungusa.org/site/pp.asp?c¼dvLUK9O0E&b¼35012
Shands Healthcare:
http://www.shands.org/health/information/article/000103.htm
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